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Objective: To determine the laboratory-based performance and operational characteristics of three dual rapid
diagnostic tests (RDTs) for testing HIV and syphilis.Methods: Three dual RDTs (SD Bioline, Chembio, andMedMira)
were evaluated using 1514 serum specimens archived at laboratories or collected from clinics in China and Nigeria
to determine sensitivity and speciﬁcity, with 95% conﬁdence intervals. Concordance of testing results read by two
technicians, stability of testing results read at two time points, and test operation characteristics were also assessed.
Results: All three of the evaluated RDTs gave excellent performance with a combined sensitivity ranging from
99.0%–99.6% for HIV and 98.3%–99.0% for syphilis, and a combined speciﬁcity ranging from 97.9%–99.0% for HIV
and 97.2%–99.6% for syphilis. Concordance of testing results between two technicians and stability of testing results
read within and one hour past the recommended reading period showed excellent agreement, with Kappa greater
than or equal to 0.98. Conclusions: All the tests were found to be very or fairly easy to use and easy to interpret the
results. Further evaluations of these dual RDTs with whole blood in ﬁeld settings, and more studies on the
implication of introduction of these tests in HIV and syphilis control programs are needed.
© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
In 2008, 1.4 million pregnant women were estimated to be infected
with syphilis worldwide, resulting in more than 520 000 adverse preg-
nancy outcomes, particularly in low-resource countries [1]. In 2013,
there were more than 1.4 million pregnant women with HIV in low-
and middle-income countries, with an estimated 240 000 children
newly infected with HIV [2]. Thus, the elimination of mother-to-child
transmission (EMTCT) of HIV and syphilis would directly contribute to-
ward the attainment of Millennium Development Goals 4, 5, and 6, as
well as the post-2015 goals. To achieve these goals, initiatives for the
dual EMTCT of HIV and syphilis have been launched at global and region-
al levels [3–5]. As one of the important components of these initiatives,
early diagnosis and timely intervention of pregnant women infected
with HIV and/or syphilis is critical to reducematernal morbidity and on-
ward transmission from mother to fetus [6,7].TD Control and Institute of
Peking Union Medical College,
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behalf of International Federation ofSerological tests are the diagnostic tests of choice for syphilis and
HIV. With regards to syphilis, both treponemal (e.g., Treponema
pallidum particle agglutination assay [TPPA] or Treponema pallidum
hemagglutination assay [TPHA]) and non-treponemal (e.g., rapid
plasma reagin [RPR]) tests can be used for laboratory diagnosis; tra-
ditionally, a non-treponemal assay is used for screening and a trepo-
nemal assay is used for conﬁrmation. Enzyme immunoassays (EIAs)
are used for HIV screening and, in high-resource settings, Western
blotting is used for conﬁrmation. All of the above tests are performed
on serum or plasma derived from venous whole blood for screening
of symptomatic and asymptomatic patients.
Screening of pregnant women for syphilis is recommended policy in
most countries [8]; despite this, more than 520 000 adverse outcomes
are recorded annually following maternal syphilis [1]. In some coun-
tries, despite the majority of pregnant women having access to antena-
tal care (ANC), only a small proportion of them undergo HIV and/or
syphilis screening. For example, in 2012, more than 60% of pregnant
women in Nigeria received ANC, but only 33% were screened for syphi-
lis, and in some North East areas of the country only less than 10% of
pregnant women were screened [9]. The infrastructure and resources
required by the traditional assays, namely well-equipped laboratories
with trained personnel, present a major barrier to testing uptake [10].Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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leading to loss to follow-up or lack of patient information.
To improve the screening and treatment coverage of pregnant
women, a number of single rapid diagnostic tests (RDTs) for HIV or syph-
ilis have been developed and scaled up [11,12], with several countries
having recently adopted RDTs into their national antenatal HIV and syph-
ilis screening policies [13]. However, use of two single RDTs usually re-
quires two sets of procedures for specimen collection, test performance,
and result reading, potentially leading to a signiﬁcant increase in work-
load in busy clinic settings. In addition, the separate logistics, suppliers,
and procurements of the two single RDTs could lead to stockouts. Recent-
ly, dual RDTs that can be used at point-of-care for simultaneously detect-
ing antibodies to HIV and syphilis (dual HIV and syphilis treponemal
RDTs) have been developed for use with venous whole blood, serum/
plasma, and/or ﬁnger-stick whole blood. At least three dual RDTs
(Chembio DPP HIV-Syphilis Assay, Chembio Diagnostic Systems Inc.,
USA; Multiplo Rapid TP/HIV Antibody Test, MedMira Inc., Canada; and
SD HIV/Syphilis Duo, Standard Diagnostics Inc., Korea) are now available.
Despite these tests having shown encouraging performance in terms of
sensitivities and speciﬁcities as compared with reference tests in studies
supported by themanufacturers [14], data from independent evaluations
from laboratories in low-resource countries are limited. The present study
aims to determine the laboratory-based performance of the three dual
HIV/syphilis RDTs mentioned above compared with current reference
standard assays and to assess the operational characteristics of these
tests in China and Nigeria.
2. Materials and methods
Laboratory-based evaluation studieswere conducted at theNational
STD Reference Laboratory of the National Center for STD Control
(NCSTD) at the Center for Disease Control and Prevention, China, and
the laboratories of the University College Hospital (UCH) in Ibadan,
Southern Nigeria, and the Ahmadu Bello University Teaching Hospital
(ABUTH) in Zaria, Northern Nigeria. These are the leading national lab-
oratories qualiﬁed to conduct serological tests for HIV and syphilis in
their respective countries and have participated in HIV and syphilis
proﬁciency programs organized by WHO, the US Centers for Disease
Control and Prevention, or their national HIV/AIDS and sexually
transmitted infection programs.
A common protocol for the evaluation studieswas prepared byWHO
with inputs from the two study countries. The current laboratory perfor-
mance studies were reviewed and approved by the WHO Ethics Review
Committee, the Ethics Committee of the Hospital for Skin Diseases of the
Chinese Academy of Medical Sciences, and the National Health Research
Ethics Committee of Nigeria. In China, serum specimens archived from
previous projects conducted by the NCSTD in multiple sites within the
country were used. At the ABUTH site in Nigeria, specimens came from
routine clinical services and, at the UCH Ibadan site in Nigeria, specimens
were collected from its antenatal clinic and special treatment clinic as
well as other hospitals and primary healthcare centers in Oyo State.
The sample size estimation was based on selection of 50% of specimens
with EIA-based HIV or TPHA/TPPA-based syphilis positivity for the eval-
uation and an expected point sensitivity of 99% with precision of 1% for
the HIV or syphilis part of the evaluation kit. A total of 760 (380 positive
and 380 negative for HIV, half of each positive or negative for syphilis)
were needed for the evaluation.
The dual RDTs under evaluation were voluntarily donated by the
manufacturers, but all other external funding for the studies came from
WHO, the Program for Appropriate Technology in Health, and the Bill
and Melinda Gates Foundation. However, the manufacturers were not
involved in study design, data collection, data analysis, data interpreta-
tion, or writing of the report. The reference tests used as gold standard
were selected according to the assays used in the evaluation laboratories
and could be considered as evaluation reference tests. At NCSTD, the
anti-HIV/P24 (HIV Ag/Ab) assay (fourth-generation HIV-EIA assay,Beijing Chemclin Biotech Co. Ltd, China) and the Serodia TPPA assay
(Fujirebio Diagnostics Inc., Japan) were used as reference tests for HIV
and syphilis, respectively. At UCH, the ELISA kit (Genscreener Plus HIV
Ag-Ab, BIO-RAD, France) and the TPHA assay (Alington Scientiﬁc Inc.,
USA) were used for HIV and syphilis, respectively. Finally, at ABUTH,
the HIV-1/2 Ag/Ab fourth-generation ELISA kit (Accu Diagnostics, CA,
USA) and the Labkit TPHA assay (Chemelex SA, Spain) were used for
HIV and syphilis, respectively.
A convenience sampling strategywas used to prepare the specimens
for evaluation. All specimens with a volume of at least 60 μL were in-
cluded. Each of the three RDTs, at all sites, was performed according to
the manufacturer’s instructions by Technician 1; test results were read
within the reading time-frame as recommended by the protocol and re-
corded in the data recording form. Simultaneously, the same procedure
to read the results was performed independently by Technician 2, who
recorded the results in a separate data recording form. At NCSTD, the
two technicians read and recorded the results again, independently,
one hour later to evaluate test stability.
At all three sites, technicians conducting the evaluation were asked
to assign, for each test, a score for the individual operational character-
istics (clarity of kit instruction, ease of use, ease of interpretation of re-
sults, rapidity of test results, hands-on time, and training time
required), as previously described [15].
The performance of the RDTs in terms of sensitivity and speciﬁcity,
alongwith their 95% conﬁdence intervals (CIs), was determined in com-
parison with the reference tests. The inter-reader consistency and the
reading time stability were evaluated according to agreement between
the two technicians and between the two reading times (those within
the reading time-frame and one hour later), using the Kappa value. In
addition, operational characteristics were scored following consensus
by the two technicians. The χ2 test was used for statistical comparison.
Analyses were performed with IBM SPSS version 19.0 (IBM, Armonk,
NY, USA) and MedCalc software package version 12.2.1 (MedCalc Soft-
ware, Mariakerke, Belgium).
3. Results
A total of 1514 specimens (754 archived at NCSTD, 380 clinically col-
lected at UCH, and 380 archived at ABUTH) were included in the study,
among which 728 (48.1%) were positive for HIV, 735 (48.5%) positive
for syphilis, and 496 (32.8%) positive for both HIV and syphilis as iden-
tiﬁed by the corresponding reference tests (Table 1).
Invalid tests occurred in 1 (0.07%), 5 (0.33%), and 2 (0.13%) tests
conducted with Chembio, MedMira, and SD Bioline RDTs for HIV or
syphilis detection, respectively. The performance results of the three
RDTs against the reference tests for HIV and syphilis, in terms of sensi-
tivity and speciﬁcitywithin 95% CIs, are shown in Table 2. All three RDTs
showed encouraging laboratory performance for detection of HIV anti-
bodies with a combined sensitivity of 99.6% (95% CI, 98.8%–99.9%) for
Chembio, 99.5% (95% CI, 99.4%–99.8%) for MedMira, and 99.0%
(95% CI, 98.0%–99.5) for SD Bioline, and a combined speciﬁcity of
97.9% (95% CI, 96.7%–98.7%), 98.3% (95% CI, 97.2%–99.0%), and 99.0%
(95.% CI, 98.0%–99.5%), respectively. The combined sensitivity and
speciﬁcity for identifying treponemal antibodies were 97.0% (95% CI,
95.5%–98.0%) and 99.6% (95% CI, 98.9%–99.9%) for Chembio, 94.2%
(95% CI, 92.3%–95.7%) and 97.2% (95% CI, 95.8%–98.1%) for MedMira,
and 96.6% (95% CI, 95.0%–97.7%) and 99.1% (95% CI, 98.2%–99.6%) for
SD Bioline. No signiﬁcant differences in the combined sensitivity or
combined speciﬁcity for HIVwere found among the three dual RDTs, al-
though the MedMira test had a lower combined sensitivity (94.1%) and
speciﬁcity (97.3%; P b 0.05).
The sensitivity for HIV was comparable across the three sites
(P N 0.05), but its speciﬁcity was lower at ABUTH for SD Bioline
(97.9%) and MedMira (95.8%; P b 0.05). A lower sensitivity was ob-
served at NCSTD for syphilis detection using Chembio (95.7%) or
MedMira (90.5%; P b 0.05), as well as a lower speciﬁcity for syphilis
Table 1
Serum specimens used for laboratory-based evaluation in three study sites.
Evaluation site Specimen source Specimen categorya Total
HIV+/TP+ HIV+/TP− HIV−/TP+ HIV−/TP−
National center for STD Control, China Archived at laboratory 216 132 139 267 754
University College Hospital, Nigeria Collected in clinics 140 50 50 140 380
Ahmadu Bello University Teaching Hospital, Nigeria Archived at laboratory 140 50 50 140 380
Total — 496 232 239 547 1514
a HIV+ and HIV−were deﬁned as positivity and negativity for EIA-based detection of antibodies against HIV 1/2, respectively; TP+ and TP−were deﬁned as positivity and negativity for
TPPA- or TPHA-based detection of treponemal antibodies, respectively.
Table 2
Performance of three dual rapid diagnostic tests for HIV/syphilis compared with respective reference tests.
Rapid diagnostic test by evaluation site Comparison with HIV ELISA Comparison with TPPA/TPHA
Sensitivity (%) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
National Center for STD Control, China
Chembio 99.2 97.2 95.7a 99.8
MedMira 99.2 98.7 90.5a 96.1a
SD Bioline 98.9 99.0 95.7 99.5
University College Hospital, Nigeria
Chembio 100.0 100.0 98.9 100.0
MedMira 99.5 100.0 98.9 98.9
SD Bioline 98.4 100.0 97.4 97.4a
Ahmadu Bello University Teaching Hospital, Nigeria
Chembio 100.0 97.4 97.4 98.9
MedMira 100.0 95.8a 96.3 97.9
SD Bioline 100.0 97.9a 97.4 100.0

























Abbreviations : ELISA, enzyme-linked immunosorbent assay; TPHA, Treponema pallidum hemagglutination assay; TPPA, Treponema pallidum particle agglutination assay.
a Statistical signiﬁcance at P b 0.05 by χ2 test compared with other study sites or other rapid diagnostic tests.
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syphilis using SD Bioline (97.4%; P b 0.05).
As shown in Table 3, agreement in testing results between the two
technicians (Kappa ≥0.99) or between the two reading time-frames
(Kappa ≥0.98) was excellent, indicating that all three of the RDTs had
an almost perfect concordance (or repeatability) of results regardless
of test conductor or time taken to read. The scores for operational char-
acteristics are summarized in Table 4. The SD Bioline test obtained the
highest score (15/16) with a signiﬁcant superiority on clarity of kitTable 3
Agreement in testing results read by two conductors and over two time points.
Rapid diagnostic test by evaluation site HIV
No.
Concordance of testing resultsa








Stability of testing resultsb




Abbreviation: RDT, rapid diagnostic test; 95% CI, 95% conﬁdence interval.
a Concordance was assessed using agreement of testing results read by two technicians inde
b Stability was assessed using agreement of testing results read by a technician within the tinstruction and ease of use. All RDTs provided results promptly; however,
SD Bioline had relatively clearer instructions, a simpler testing procedure,
and a short training time.
4. Discussion
In addition to behavioral interventions, biomedical interventions
are increasingly important for the successful control and EMTCT of
HIV and syphilis. Early diagnosis and timely treatment of infectedcomponent in RDT Syphilis component in RDT
Agreement, % Kappa (95% CI) No. Agreement, % Kappa (95% CI)
99.9 1.00 (0.99–1.00) 754 100.0 1.00 (1.00–1.00)
100.0 1.00 (1.00–1.00) 754 100.0 1.00 (1.00–1.00)
99.5 0.99 (0.98–1.00) 754 99.9 1.00 (0.99–1.00)
99.5 1.00 (1.00–1.00) 760 99.7 1.00 (1.00–1.00)
99.6 1.00 (1.00–1.00) 760 99.6 1.00 (1.00–1.00)
100.0 1.00 (1.00–1.00) 760 100 0.99 (0.98–1.00)
99.1 0.98 (0.97–0.99) 754 98.9 0.98 (0.96–0.99)
99.6 0.99 (0.98–1.00) 754 99.3 0.99 (0.98–1.00)
99.7 0.99 (0.99–1.00) 754 99.2 0.98 (0.97–1.00)
pendently.
ime speciﬁed in the manufacturer’s protocol and 1 hour later.
Table 4
Operational characteristics of three dual rapid diagnostic tests for HIV/syphilis.
Operational characteristics Top score Mean score
Chembio MedMira SD Bioline
Clarity of kit instruction 3 1.7 1.5 3.0
Ease of use 3 2.0 1.7 3.0
Ease of interpretation of results 3 2.3 2.3 3.0
Rapidity of test results 2 2.0 2.0 2.0
Hands-on time 2 1.0 1.0 1.0
Training time required 3 2.0 2.0 3.0
Total 16 11.0 10.5 15.0
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17]. Routine screening for HIV and syphilis is recommended by
WHO for women attending ANC since its effective implementation
can reduce adverse outcomes during pregnancy [3,18]. Dual RDTs
are an efﬁcient tool for the creation of an integrated and functional
platform to simultaneously detect HIV and syphilis infections dur-
ing routine ANC visits and offer a unique opportunity to achieve
the dual EMTCT of HIV and syphilis. The current study has a larger
number of positive HIV or syphilis specimens compared with previous
studies [14,19].
The above results indicate that all three of the dual RDTs have an
acceptable sensitivity and speciﬁcity to detect HIV or syphilis, al-
though the sensitivity to detect HIV antibodies (99.0%–99.6%) is
generally higher than that for syphilis (94.2%–97.0%). The HIV test-
ing sensitivity reported herein is similar to that reported by the in-
dividual manufacturers for the three dual RDTs as well as to that
recently reported following a multisite evaluation study for SD
Bioline in Africa [14]. However, the sensitivity for syphilis testing
was generally lower than in previous reports [20]. Nevertheless,
the sensitivities and speciﬁcities of the three dual RDTs met the
minimal or optimal criteria for performance characteristics de-
scribed in the target product proﬁle [21], despite there being differ-
ences in sensitivity and/or speciﬁcity between study sites or RDTs.
Of note, however, the target product proﬁle requires whole blood
ﬁnger-prick specimens to determine performance, whereas serum
specimens were used herein. Therefore, further evaluations using
ﬁnger-prick blood specimens are required.
The low variability between the three RDTs with respect to
inter-reader consistency or the two time-frames suggests a high
coherence and stability over time, which will be of immense ben-
eﬁt in busy or under-staffed ANC clinic settings in low-resource
countries. These data may be useful for RDT manufactures to con-
sider extending or simplifying the reading window. The clarity of
operational instructions provided by the manufacturers was well un-
derstood and the simplicity of testing processes was easily handled by
the operators, in particular for SD Bioline. In addition, evaluation of
the operational characteristics suggests that all three tests show ease
of use and result interpretation.
The introduction of tests in primary care settings can pose consider-
able challenges and difﬁculties, even for tests with acceptable perfor-
mance in laboratory evaluations [22]. Further research on dual RDTs is
needed to evaluate their performance with whole blood samples in pri-
mary care settings and to deﬁne the economic and programmatic impli-
cations of their use. This laboratory evaluation in China and Nigeria is
part of a comprehensive package of evaluations proposed by WHO
and the study team. In addition, a ﬁeld-based evaluation study using
ﬁnger-prickwhole blood fromwomen attending ANC clinics to validate
the performance is underway in Zambia, as are introduction studies to
determine the testing uptake, feasibility, and acceptability of introduc-
ing dual RDTs in ANC services in China, Colombia, and Nigeria. It is
hoped that this research package will provide data to guide other
countries as to the value of dual HIV/syphilis RDTs and inform future
development of WHO guidelines.5. Conclusions
All three dual RDTs evaluated in the present study showed
acceptable sensitivity and speciﬁcity in testing for HIV-1/2 and trepone-
mal antibodies from archived or clinical serum specimens in China and
Nigeria. Owing to the ease/simplicity of procedures and interpretation
of test results, these dual RDTs can serve as alternatives to the more
cumbersome, demanding, and expensive conventional screening
methods or single RDTs for HIV and syphilis, especially in resource-
limited countries. These dual tests would not only simplify HIV and
syphilis testing, but would also be more cost-effective and patient-
friendly because of the need for a single blood sample [19]. Dual RDTs
may thus be a key tool to accelerate the dual EMTCT of HIV and syphilis.
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